1 |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
|
2 |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1):35-43.
|
3 |
Xu X, Di L, Qi L, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6):1035-1041.
|
4 |
Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors[J]. Ann Surg, 2020, 272(5): 855-862.
|
5 |
Buchholz BM, Ferguson JW, Schnitzbauer AA, et al. Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function[J]. Transplantation, 2020,104(5):1003-1018.
|
6 |
Fan GH, Zhang CZ, Gao FQ, et al. A mixed blessing for liver transplantation patients-rapamycin[J]. Hepatobiliary Pancreat Dis Int, 2023, 22(1):14-21.
|
7 |
Chen J, Shen T, Li J, et al. Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition) [J]. Chin Med J (Engl), 2022, 135(24):2911-2913.
|
8 |
Yan X, Huang S, Yang Y, et al. Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Liver Transpl, 2022, 28(6):1063-1077.
|
9 |
Choi HJ, Park JH, Kim OH, et al. Combining everolimus and Ku0063794 promotes apoptosis of hepatocellular carcinoma cells via reduced autophagy resulting from diminished expression of miR-4790-3p[J]. Int J Mol Sci, 2021, 22(6):2859.
|
10 |
Lee SC, Kim KH, Kim OH, et al. Everolimus plus Ku0063794 regimen promotes anticancer effects against hepatocellular carcinoma cells through the paradoxical inhibition of autophagy[J]. Cancer Res Treat, 2018,50(3):1023-1038.
|
11 |
Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex[J]. Nature, 1994, 369(6483):756-758.
|
12 |
Choi J, Chen J, Schreiber SL, et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP[J]. Science, 1996,273(5272):239-242.
|
13 |
Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J]. Science, 2005, 307(5712):1098-1101.
|
14 |
Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019,12(1):71.
|
15 |
Zeng Z, Sarbassov dos D, Samudio IJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML[J]. Blood, 2007, 109(8):3509-3512.
|
16 |
Shim S, Yoon BH, Shin IS, et al. Network meta-analysis: application and practice using Stata[J]. Epidemiol Health, 2017, 39:e2017047.
|
17 |
Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis[J]. BMJ, 2013, 346: f2914.
|
18 |
田金徽,葛龙,赵晔,等. 网状Meta分析优先报告条目:PRISMA扩展声明解读[J]. 中国药物评价,2015(5):266-272.
|
19 |
Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions[J]. Cochrane Database Syst Rev, 2019,10(10):ED000142.
|
20 |
Brooks SP, Gelman AE. General methods for monitoring convergence of iterative simulations[J]. J Comput Graph Stat, 1988,7(4):434-455.
|
21 |
Tunaru R. Hierarchical Bayesian models for multiple count data[J]. Aust Nz J Stat, 2002, 31(3):221-229.
|
22 |
Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Liver Transpl, 2009,15(12):1834-1842.
|
23 |
Cholongitas E, Goulis I, Theocharidou E, et al. Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience[J]. Hepatol Int, 2014, 8(1):137-145.
|
24 |
Cillo U, Saracino L, Vitale A, et al. Very early introduction of everolimus in de novo liver transplantation: results of a multicenter, prospective, randomized trial[J]. Liver Transpl, 2019,25(2):242-251.
|
25 |
Ekpanyapong S, Philips N, Loza BL, et al. Predictors, presentation, and treatment outcomes of recurrent hepatocellular carcinoma after liver transplantation: a large single center experience[J]. J Clin Exp Hepatol, 2020,10(4):304-315.
|
26 |
Ferreiro AO, Vazquez-Millán MA, López FS, et al. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series[J]. Transplant Proc, 2014, 46(10):3496-3501.
|
27 |
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1):116-125.
|
28 |
Junge G, Fischer L, Schemmer P, et al. Everolimus, mtorc1 inhibition, and impact on hepatocellular carcinoma recurrence after liver transplantation-12, 24, and 36 months data from 719 ltx recipients[J]. Transpl Int, 2014, 27:23.
|
29 |
Kang I, Lee JG, Choi SH, et al. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma[J]. Clin Mol Hepatol, 2021, 27(4):589-602.
|
30 |
Lee SG, Jeng LB, Saliba F, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials[J]. Transplantation, 2021, 105(7):1564-1575.
|
31 |
Ling S, Feng T, Zhan Q, et al. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria[J]. Ann Transl Med, 2020, 8(4):80.
|
32 |
Liu P, Wang X, Liu H, et al. Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: a single-center experience[J]. Hepatobiliary Pancreat Dis Int, 2023, 22(1):34-40.
|
33 |
Manzia TM, Angelico R, Toti L, et al. Ab initio everolimus-based versus standard calcineurin inhibitor immunosuppression regimen in liver transplant recipients[J]. Transplant Proc, 2018,50(1):175-183.
|
34 |
Rodríguez-Perálvarez M, Guerrero M, Barrera L, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplantation, 2018,102(12):2056-2064.
|
35 |
Sapisochin G, Lee WC, Joo DJ, et al. Long-term effects of everolimus-facilitated tacrolimus reduction in living-donor liver transplant recipients with hepatocellular carcinoma[J]. Ann Transplant, 2022, 27:e937988.
|
36 |
Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma[J]. BMC Cancer, 2010,10:190.
|
37 |
Shen C, Peng C, Shen B, et al. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation[J]. Oncotarget, 2016,7(38):62647-62656.
|
38 |
Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial[J]. Liver Transpl, 2013, 19(7):675-689.
|
39 |
Thorat A, Jeng LB, Yang HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg, 2017, 21(4):205-211.
|
40 |
Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J]. Hepatology, 2010,51(4):1237-1243.
|
41 |
Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma[J]. Transplantation, 2010,89(2):227-231.
|
42 |
Xu SL, Zhang YC, Wang GY, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2016,40(6), 674-681.
|
43 |
Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl,2016, 22(5): 627-634.
|
44 |
赵晓飞,卢实春,王孟龙,等. 西罗莫司影响原发性肝细胞癌肝移植患者术后远期生存的回顾性队列研究[J]. 中华外科杂志,2014, 52(4):245-248.
|
45 |
Zhou J, Wang Z, Wu ZQ, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria[J]. Transplant Proc, 2008, 40(10):3548-3553.
|
46 |
Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Liver Transpl, 2008,14(5):633-638.
|
47 |
Bhangui P, Roy R, Saigal S, et al. Can sirolimus-switch post liver transplantation in patients with hepatocellular carcinoma improve survival outcomes?[J]. Transplantation,2016, 100(Suppl 5):S190.
|
48 |
Lee KW, Kim SH, Yi NJ, et al. Sirolimus prolonged survival after living donor liver transplantation for HCC beyond milan criteria; outcome of a multicenter prospective randomized phase Ⅱ trial[C/OL]//2017 American Transplant Congress, Chicago, 2017[2023-08-05].
URL
|
49 |
Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society Consensus Statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018,102(5):727-743.
|
50 |
Kim JM. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?[J]. Clin Mol Hepatol, 2021, 27(4):562-563.
|
51 |
俞祺健,杨喆,郑树森. 预防肝癌肝移植术后肿瘤复发的研究现状及进展[J]. 中华移植杂志:电子版,2023,17(3):171-179.
|
52 |
Kim M, Rhu J, Choi GS, et al. Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation[J]. Ann Surg Treat Res, 2021, 101(1):28-36.
|
53 |
中国器官移植发展基金会器官移植受者健康管理专家委员会,中国医师协会器官移植医师分会,中华医学会器官移植学分会,等. 肝移植受者雷帕霉素靶蛋白抑制剂临床应用中国专家共识(2023版)[J]. 中华移植杂志:电子版,2023,17(4):193-204.
|
54 |
Ferrer-Fàbrega J, Forner A, Liccioni A, et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection[J]. Hepatology, 2016, 63(3):839-849.
|
55 |
Lin WP, Xing KL, Fu JC, et al. Development and validation of a model including distinct vascular patterns to estimate survival in hepatocellular carcinoma[J]. JAMA Netw Open, 2021,4(9):e2125055.
|
56 |
周少来,周俭. 肝癌复发转移的防治[J]. 肝胆胰外科杂志,2022,34(7):385-388.
|